A total of 1404 patients were included into the remaining four randomized trials, formally combined to the group "other", which evaluated the combination of gemcitabine with the multitarget antifolate pemetrexed or the topoisomerase inhibitors irinotecan or exatecan (Tables 3, 8, 9).
We evaluated the combination of NT-proBNP and coronary artery calcium score (CAC) for prediction of combined fatal and non-fatal CVD and mortality in patients with type 2 diabetes and microalbuminuria (>30 mg/24-h), but without known coronary artery disease.
The present phase II study (ClinicalTrials.gov identifier, NCT01934894) evaluated the combination of these agents to treat HER2+ MBC patients with CNS metastases.
We have evaluated the combination of adipose tissue-derived adult stem cells (ADSCs) obtained from autologous liposuction and injectable poly(lactic-co-glycolic acid) (PLGA) spheres for muscle regeneration.
No studies evaluated the combination of LUS and PCT for the diagnosis of pneumonia in the emergency department (ED).
We further evaluated the combination of an AKI biomarker, plasma neutrophil gelatinase-associated lipocalin (NGAL), and FR for predicting AKI progression.
Preclinical studies have evaluated the combination of temozolomide with other alkylating agents and inhibitors of the DNA repair protein O6-alkylguanine alkyltransferase to overcome resistance to chemotherapy in malignant glioma and malignant metastatic melanoma.
We successfully evaluated the combination of pentachloronitrobenzene and vancomycin added to the yeast-mannitol medium to inhibit most fungi and Gram-positive soybean microbiota, thus producing reliable counts of B. japonicum from inoculated soybean seeds.
In this study, we retrospectively evaluated the combination of AKI biomarkers and urine output in response to the administration of bolus furosemide for stratifying the risk of AKI progression in critically ill patients.
We evaluated the combination of MR-proADM and SOFA score in predicting mortality, such that patients with MR-proADM concentrations >1.79 nmol/L were considered to have a 1 point increase in the SOFA score.
We therefore evaluated the combination of Ad-stTRAIL and BCNU, in vitro and in vivo.
